Boelen, L;
Debebe, B;
Silveira, M;
Salam, A;
Makinde, J;
Roberts, C;
Wang, E;
Frater, J;
Gilmour, J;
Twigger, K;
et al.
Boelen, L; Debebe, B; Silveira, M; Salam, A; Makinde, J; Roberts, C; Wang, E; Frater, J; Gilmour, J; Twigger, K; Ladell, K; Miners, K; Jayaraman, J; Traherne, J; Price, D; Qi, Y; Martin, M; Macallan, DC; IAVI Protocol C Investigators; Thio, C; Astemborski, J; Kirk, G; Donfield, S; Buchbinder, S; Khakoo, S; Goedert, J; Trowsdale, J; Carrington, M; Kollnberger, S; Asquith, B
(2018)
Inhibitory killer-cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV and HTLV-1.
Science Immunology, 3 (29).
eaao2892.
ISSN 2470-9468
https://doi.org/10.1126/sciimmunol.aao2892
SGUL Authors: Macallan, Derek Clive
|
PDF
Accepted Version
Available under License ["licenses_description_publisher" not defined]. Download (5MB) | Preview |
|
|
PDF (Supplementary information)
Accepted Version
Available under License ["licenses_description_publisher" not defined]. Download (1MB) | Preview |
Abstract
Killer cell immunoglobulin-like receptors (KIRs) are expressed predominantly on natural killer cells, where they play a key role in the regulation of innate immune responses. Recent studies show that inhibitory KIRs can also affect adaptive T cell–mediated immunity. In mice and in human T cells in vitro, inhibitory KIR ligation enhanced CD8+ T cell survival. To investigate the clinical relevance of these observations, we conducted an extensive immunogenetic analysis of multiple independent cohorts of HIV-1–, hepatitis C virus (HCV)–, and human T cell leukemia virus type 1 (HTLV-1)–infected individuals in conjunction with in vitro assays of T cell survival, analysis of ex vivo KIR expression, and mathematical modeling of host-virus dynamics. Our data suggest that functional engagement of inhibitory KIRs enhances the CD8+ T cell response against HIV-1, HCV, and HTLV-1 and is a significant determinant of clinical outcome in all three viral infections.
Item Type: | Article | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Additional Information: | This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Immunology on Vol 3, 9 Nov 2018, DOI: 10.1126/sciimmunol.aao2892. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal or Publication Title: | Science Immunology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ISSN: | 2470-9468 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publisher License: | Publisher's own licence | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Projects: |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/110261 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publisher's version: | https://doi.org/10.1126/sciimmunol.aao2892 |
Statistics
Actions (login required)
![]() |
Edit Item |